BioNTech doses first patient in herpes vaccine study

The following is an excerpt from Reuters. BioNtech has dosed the first patient with its BNT163 herpes vaccine candidate designed to prevent genital lesions as part of a first-in-human Phase 1 clinical research study, the German vaccine maker said on Wednesday. The vaccine candidate is meant to prevent HSV-2, the herpes simplex virus that causes […]

Share DeepPol